These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

430 related items for PubMed ID: 17404192

  • 1. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease.
    Pahwa R, Stacy MA, Factor SA, Lyons KE, Stocchi F, Hersh BP, Elmer LW, Truong DD, Earl NL, EASE-PD Adjunct Study Investigators.
    Neurology; 2007 Apr 03; 68(14):1108-15. PubMed ID: 17404192
    [Abstract] [Full Text] [Related]

  • 2. Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease: a 16-week bromocriptine controlled study.
    Im JH, Ha JH, Cho IS, Lee MC.
    J Neurol; 2003 Jan 03; 250(1):90-6. PubMed ID: 12527999
    [Abstract] [Full Text] [Related]

  • 3. Ropinirole is effective on motor function when used as an adjunct to levodopa in Parkinson's disease: STRONG study.
    Mizuno Y, Abe T, Hasegawa K, Kuno S, Kondo T, Yamamoto M, Nakashima M, Kanazawa I, STRONG Study Group.
    Mov Disord; 2007 Oct 15; 22(13):1860-5. PubMed ID: 17618525
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetic and pharmacodynamic comparison of ropinirole 24-hour prolonged release and ropinirole immediate release in patients with Parkinson's disease.
    Tompson D, Oliver-Willwong R.
    Clin Neuropharmacol; 2009 Oct 15; 32(3):140-8. PubMed ID: 18978485
    [Abstract] [Full Text] [Related]

  • 5. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.
    Parkinson Study Group.
    Arch Neurol; 2005 Feb 15; 62(2):241-8. PubMed ID: 15710852
    [Abstract] [Full Text] [Related]

  • 6. [Improvements in motor and non-motor symptoms in parkinson patients under ropinirole therapy].
    Buchwald B, Angersbach D, Jost WH.
    Fortschr Neurol Psychiatr; 2007 Apr 15; 75(4):236-41. PubMed ID: 17427044
    [Abstract] [Full Text] [Related]

  • 7. Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease.
    Watts RL, Lyons KE, Pahwa R, Sethi K, Stern M, Hauser RA, Olanow W, Gray AM, Adams B, Earl NL, 228 Study Investigators.
    Mov Disord; 2010 May 15; 25(7):858-66. PubMed ID: 20461803
    [Abstract] [Full Text] [Related]

  • 8. Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations.
    Hersh BP, Earl NL, Hauser RA, Stacy M.
    Mov Disord; 2010 May 15; 25(7):927-31. PubMed ID: 20461810
    [Abstract] [Full Text] [Related]

  • 9. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R, Baker WL, Patel AA, Reinhart K, Coleman CI.
    Int J Clin Pract; 2009 Apr 15; 63(4):613-23. PubMed ID: 19222614
    [Abstract] [Full Text] [Related]

  • 10. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa.
    Hauser RA, Rascol O, Korczyn AD, Jon Stoessl A, Watts RL, Poewe W, De Deyn PP, Lang AE.
    Mov Disord; 2007 Dec 15; 22(16):2409-17. PubMed ID: 17894339
    [Abstract] [Full Text] [Related]

  • 11. A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease.
    Stacy M, Silver D, Mendis T, Sutton J, Mori A, Chaikin P, Sussman NM.
    Neurology; 2008 Jun 03; 70(23):2233-40. PubMed ID: 18519872
    [Abstract] [Full Text] [Related]

  • 12. Orally disintegrating selegiline in Parkinson patients with dopamine agonist-related adverse effects.
    Lyons KE, Friedman JH, Hermanowicz N, Isaacson SH, Hauser RA, Hersh BP, Silver DE, Tetrud JW, Elmer LW, Parashos SA, Struck LK, Lew MF, Pahwa R.
    Clin Neuropharmacol; 2010 Jun 03; 33(1):5-10. PubMed ID: 19855267
    [Abstract] [Full Text] [Related]

  • 13. A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson's disease.
    Brooks DJ, Abbott RJ, Lees AJ, Martignoni E, Philcox DV, Rascol O, Roos RA, Sagar HJ.
    Clin Neuropharmacol; 1998 Jun 03; 21(2):101-7. PubMed ID: 9579296
    [Abstract] [Full Text] [Related]

  • 14. An open-label conversion study of pramipexole to ropinirole prolonged release in Parkinson's disease.
    Lyons KE, Pahwa R.
    Mov Disord; 2009 Oct 30; 24(14):2121-7. PubMed ID: 19768728
    [Abstract] [Full Text] [Related]

  • 15. Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease.
    Hauser RA, Schapira AH, Rascol O, Barone P, Mizuno Y, Salin L, Haaksma M, Juhel N, Poewe W.
    Mov Disord; 2010 Nov 15; 25(15):2542-9. PubMed ID: 20669317
    [Abstract] [Full Text] [Related]

  • 16. Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group.
    Rascol O, Brooks DJ, Brunt ER, Korczyn AD, Poewe WH, Stocchi F.
    Mov Disord; 1998 Jan 15; 13(1):39-45. PubMed ID: 9452324
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effects of ropinirole prolonged-release on sleep disturbances and daytime sleepiness in Parkinson disease.
    Dusek P, Busková J, Růzicka E, Majerová V, Srp A, Jech R, Roth J, Sonka K.
    Clin Neuropharmacol; 2010 Jul 15; 33(4):186-90. PubMed ID: 20661025
    [Abstract] [Full Text] [Related]

  • 19. Ropinirole therapy for Parkinson's disease.
    Pahwa R, Lyons KE, Hauser RA.
    Expert Rev Neurother; 2004 Jul 15; 4(4):581-8. PubMed ID: 15853577
    [Abstract] [Full Text] [Related]

  • 20. Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations.
    Hauser RA, Shulman LM, Trugman JM, Roberts JW, Mori A, Ballerini R, Sussman NM, Istradefylline 6002-US-013 Study Group.
    Mov Disord; 2008 Nov 15; 23(15):2177-85. PubMed ID: 18831530
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.